Multi-Omics Approaches in Drug Discovery
Date: January 30, 2024
Join Diamond Age's scientific experts and draw on their expertise from working with their clients across biotech and pharma, plus prior employers like the Broad Institute, Dana-Farber and Novartis.
Biotechnology companies can use combinations of different types of ‘omics data to gain a more comprehensive and interconnected view of biological processes, identify biomarkers, discover therapeutic targets, and make more informed decisions in research, development, and clinical applications.
Our round table will explore how multi-omics helps biotech companies understand relationships between different molecules and pathways to:
- Identifying new drug targets
- Improving diagnostic tests
- Understanding the molecular basis of disease
Request An Invite
Our Round Table Host
Founder & CEO, Diamond Age Data Science
Broad Institute, Dana-Farber Cancer Institute, Institute for Genomic Research
Ph.D Bioinformatics from University of Oxford
Eleanor has been working at the cutting edge of bioinformatics for 20 years.
Before founding Diamond Age, Eleanor served as the sole bioinformatician in the Center for the Development of Therapeutics at the Broad Institute of MIT and Harvard, where she helped drive drug discovery projects in cancer, cardiovascular disease, and kidney disease, among others. She also worked at the Dana-Farber Cancer Institute, where she led mid- and late-stage development of the Multiexperiment Viewer, a powerful tool for mining large genomic datasets.
Trained as a computational biologist, Eleanor has deep expertise in transcriptional profiling as well as drug discovery and development. She earned her Ph.D. bioinformatics from Oxford University under Christopher Holmes and John Quackenbush, and also holds a Master’s degree in cellular and molecular biology from the University of Wisconsin-Madison.